BDNF/TrkB vs. 5-HT2A in psilocybin pharmacology: preclinical evidence & human unknowns
Executive Summary
For half a century, neuropharmacology assumed that both the acute subjective effects and the structural neuroplastic effects of psilocybin flowed through a single bottleneck: agonism of the serotonin 2A (5-HT2A) receptor. Between 2021 and 2026, three independent peer-reviewed rodent studies in Neuron, Nature Neuroscience, and Neuropsychopharmacology challenged that single-receptor assumption, demonstrating in mice and rats that dendritic spine growth and TrkB-dependent behavioral rescue persisted even when 5-HT2A receptors were blocked. Whether that dissociation holds in humans at sub-perceptual oral doses is the central clinical question Xycota Biosciences was built to test.
1. Three Converging Rodent Studies (2021 to 2026)
Institutional diligence teams evaluating non-hallucinogenic or sub-perceptual psilocybin programs consistently ask a single mechanistic question: if you lower the dose below the 5-HT2A perceptual threshold, why would any neurotrophic signal remain? Three peer-reviewed preclinical studies provide the mechanistic rationale for testing that hypothesis.
| Published Study | Preclinical Species & Model | Receptor Perturbation Tested | Primary Preclinical Observation | Translational Boundary |
|---|---|---|---|---|
| Shao & Kwan et al., Neuron (2021) Yale University |
Living male & female C57BL/6J mice (two-photon longitudinal cortex microscopy) | Ketanserin (5-HT2A/2C antagonist) pretreatment | Single psilocybin dose increased frontal-cortex dendritic spine density & head width ~10% within 24h (persisting at day 34); ketanserin blocked >80% of head-twitch behavior in mice without abolishing spine formation | Mouse structural imaging; ketanserin provides incomplete central 5-HT2A occupancy in rodents |
| Moliner & Castrén et al., Nature Neuroscience (2023) University of Helsinki |
Rodent neuronal cultures, cell-free binding assays & mouse behavioral models | Selective 5-HT2A antagonist (M100907) & TrkB point-mutation (TrkB.Y433F) | Psilocin bound directly to the transmembrane domain of TrkB dimers at nanomolar affinity (~6.7 nM), acting as a positive allosteric modulator of endogenous BDNF independent of 5-HT2A in rodent assays | Preclinical biochemical and rodent behavioral assays; human brain TrkB occupancy at low oral doses is unmeasured |
| Ascone, Trezza & Hausman et al., Neuropsychopharmacology (2026) Roma Tre University & Xycota CSO |
Male Fmr1-Δexon 8 Fragile X rats (repeated low-dose oral psilocybin, 0.1 mg/kg p.o.) | Selective 5-HT2A blockade (M100907), 5-HT1A blockade (WAY-100635), and TrkB blockade (ANA-12) | Repeated low-dose oral psilocybin normalized prefrontal mature BDNF, TrkB, and pAKT/AKT and rescued object-recognition memory in Fmr1 rats; rescue persisted under M100907 or WAY-100635 and was abolished by TrkB antagonist ANA-12 | Conducted exclusively in a genetic rat model of Fragile X Syndrome, not in humans and not in a PTSD model |
2. Why Receptor Affinity Differences Matter at Sub-Perceptual Exposures
In human positron emission tomography (PET) studies using the 5-HT2A radiotracer [11C]Cimbi-36, noticeable psychedelic effects correlate strongly with high cortical 5-HT2A receptor occupancy (typically 50% to 70%+ occupancy after macrodose psilocybin). Conversely, if psilocin's allosteric interaction with TrkB dimers occurs at lower nanomolar free brain concentrations, as reported in rodent assays by Moliner et al. (2023), a therapeutic window could theoretically exist below the threshold of overt 5-HT2A perceptual disturbance.
However, allosteric affinity in rodent tissue does not guarantee human clinical efficacy. Species differences in transmembrane TrkB residues, oral bioavailability, first-pass glucuronidation, and blood-brain-barrier free fraction mean that only a well-controlled human clinical trial can test whether a sub-perceptual oral psilocybin regimen produces a clinical signal.
3. How XYCO-02 Tests This Question Cleanly
Rather than extrapolating rodent findings into premature clinical claims, Xycota structured its lead program (XYCO-02) around three falsifiable questions in a proposed 28-day randomized, double-blind, placebo-controlled Health Canada trial in adults with mild PTSD:
- Clinical Symptom Readout: Does 28 days of standardized sub-perceptual oral dosing produce a statistically meaningful change on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) relative to matched placebo?
- Blinding Integrity: Do participant and rater treatment-guess rates remain near chance across repeated outpatient dosing?
- Exploratory Peripheral Biomarker: How do peripheral serum/plasma BDNF measurements behave alongside clinical scores (recognizing that blood BDNF alone does not prove central TrkB engagement)?
Key Diligence Questions
Did Xycota's 2026 Neuropsychopharmacology paper prove psilocybin treats human PTSD?
No. Ascone et al. (Neuropsychopharmacology, July 2026) was conducted exclusively in male Fmr1 rats, a preclinical genetic model of Fragile X Syndrome. It demonstrated TrkB-dependent memory rescue and synaptic protein normalization in rats independent of 5-HT2A blockade, providing the mechanistic hypothesis to test XYCO-02 in a future human clinical study.
Who collaborated on the 2026 Neuropsychopharmacology study?
The study was led by senior and corresponding author Associate Professor Viviana Trezza, PhD, at Roma Tre University (an external academic collaborator, not a Xycota employee) and co-authored by Xycota Co-Founder and Chief Scientific Officer Dr. Marvin S. Hausman, MD.
Institutional & Strategic Partner Access
Review Preclinical Reports, Patent Schedules & Regulatory Filings
Xycota Biosciences, LLC is an independent, privately held CNS biotechnology company headquartered in Sheridan, Wyoming. Qualified institutional life-science investors, pharmaceutical licensing teams, and clinical research partners may request NDA-gated access to the Xycota Data Room or watch our 3-minute Investor Briefing. All programs are preclinical and investigational; no securities are offered on this website.
2. Moliner R, Girych M, Brunello CA, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nature Neuroscience. 2023;26(6):1032-1041. doi:10.1038/s41593-023-01316-5.
3. Ascone F, Buzzelli V, Mottarlini F, Trezza V, Hausman MS, et al. Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway. Neuropsychopharmacology. 2026;51(8):1454-1463. doi:10.1038/s41386-026-02361-x.